American Capital Advisory’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$790K Buy
6,146
+529
+9% +$61.9K 0.29% 58
2026
Q1
$676K Sell
5,617
-222
-4% -$25.6K 0.27% 65
2025
Q4
$615K Sell
5,839
-177
-3% -$16.6K 0.27% 64
2025
Q3
$505K Buy
6,016
+10
+0.2% +$824 0.23% 71
2025
Q2
$475K Buy
6,006
+25
+0.4% +$1.99K 0.24% 69
2025
Q1
$537K Sell
5,981
-177
-3% -$16.5K 0.29% 59
2024
Q4
$613K Hold
6,158
0.34% 57
2024
Q3
$699K Buy
6,158
+4,805
+355% +$571K 0.41% 53
2024
Q2
$148K Sell
1,353
-25
-2% -$3.22K 0.11% 95
2024
Q1
$147K Buy
1,378
+25
+2% +$3.08K 0.13% 98
2023
Q4
$148K Buy
+1,353
New +$140K 0.11% 95

Other funds holding MRK

American Capital Advisory's MRK Position: Q2 2026 in Review

American Capital Advisory increased its Merck (MRK) stake by 9.4% in Q2 2026, buying an estimated $61.9K and bringing the position to 6,146 shares worth $790K. The position accounts for 0.29% of the portfolio, ranked #58.

American Capital Advisory first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 1,588 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • American Capital Advisory held 6,146 shares of Merck worth $790K as of Q2 2026.
  • American Capital Advisory bought 529 Merck shares in Q2 2026, an estimated $61.9K.
  • Merck made up 0.29% of American Capital Advisory's portfolio in Q2 2026, its #58 holding.
  • American Capital Advisory first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 1,588 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.